Cabaletta Bio Inc (CABA) is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of B cell-mediated autoimmune diseases. The company's proprietary technology platform, called the Cabaletta Approach, enables the engineering of T cells to selectively eliminate only the autoreactive B cells that cause disease while sparing healthy B cells that are critical for immune function.
Cabaletta Bio's lead product candidate is DSG3-CAART, a Chimeric AutoAntibody Receptor (CAAR) T cell therapy being developed for the treatment of mucosal pemphigus vulgaris (mPV), a rare and often debilitating autoimmune disease that affects the mucous membranes. The company is also developing other CAAR T cell therapies for the treatment of other B cell-mediated autoimmune diseases.
The company's pipeline also includes preclinical programs for the treatment of multiple sclerosis (MS) and rheumatoid arthritis (RA), as well as an early-stage program for the treatment of amyotrophic lateral sclerosis (ALS).
Cabaletta Bio was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Cabaletta Bio Inc (CABA) is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of B cell-mediated autoimmune diseases. The company's proprietary technology platform, called the Cabaletta Approach, enables the engineering of T cells to selectively eliminate only the autoreactive B cells that cause disease while sparing healthy B cells that are critical for immune function.